EPHEDRINE SULFATE

Post-LOE

ephedrine sulfate

Fresenius Kabi

ANDAINTRAVENOUSSOLUTION

Approved

Mar 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

EPHEDRINE SULFATE (ephedrine sulfate) by Fresenius Kabi is α- and β-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Approved for clinically important hypotension occurring in the setting of anesthesia. First approved in 2025.

Drug data last refreshed 19h ago

Mechanism of Action

α- and β-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. Pressor effects by direct alpha- and beta-adrenergic receptor activation are mediated by increases in arterial pressures, cardiac output, and peripheral resistance. Indirect adrenergic…

Indications (1)

clinically important hypotension occurring in the setting of anesthesia

Clinical Trials (1)

NCT01373138Phase 1Completed

Bioequivalence Study of Desloratadine and Pseudoephedrine Sulfate Extended-release Tablets Under Fasting Conditions

Started Apr 2006

34 enrolled

Healthy

Worked on EPHEDRINE SULFATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.